| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
| ln Vitro |
Acyclic deoxyguanosine analog ganciclovir (BW 759) possesses strong anti-CMV action and resembles acyclovir in structure. Compared to 72 μM for acyclovir, the median dose of ganciclovir needed to suppress viral reproduction by 50% is 2.15 μM [4]. Using ganciclovir-5'-triphosphate (ganciclovir-TP), ganciclovir inhibits viral DNA replication, which is the primary mechanism of action against CMV. Viral DNA polymerase is specifically and potently inhibited by this inhibitor. Three biological enzymes mostly convert ganciclovir to its triphosphate form: phosphoglycerate kinase, guanylate kinase, and deoxyguanosine kinase, which is activated in CMV-infected cells [5].
|
|---|---|
| ln Vivo |
For a total of five intraperitoneal injections, ganciclovir (BW 759) (50 mg/kg) drastically lowers white blood cells, red blood cells, and platelets in neonatal mice. It can also spread to the outer ear and brain. The space of lymph. 3]. In mice infected with the cytomegalovirus (MCMV), ganciclovir (1–80 mg/kg; intravenously; once daily for 5 days) postpones wasting syndrome and mortality [6].
|
| Animal Protocol |
Animal/Disease Models: non-inbred Oncins France 1 (OF1) mice and albino rats without MCMV immunization [3]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection, twice a day, for 5 consecutive injections (mouse ) or 3 days (adult rats) ) (pharmacokinetic/PK/PK study) Experimental Results: In adult rats, intracochlear diffusion of ganciclovir reaches the same concentration as in blood. In pregnant mice, transplacental spread was observed with a fetal to maternal blood ratio of 0.5. In neonatal mice, plasma concentrations of ganciclovir peak within 2 hrs (hrs (hours)) and gradually decrease thereafter. In adult mice, concentrations peaked at 1 hour but became undetectable at 2 hrs (hrs (hours)) post-injection. White blood cells, red blood cells and platelets were Dramatically diminished in newborn mice. Animal/Disease Models: Female SCID (severe combined immunodeficient) mouse vaccinated with MCMV[6] Doses: 0, 1, 10, 80 and 160 mg/kg Route of Administration: subcutaneous injection, one time/day for 5 days Experimental Results: Within a certain dose range, dose-dependent Delayed wasting syndrome |
| References | |
| Additional Infomation |
Ganciclovir Sodium can cause developmental toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Ganciclovir is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of cytomegalovirus retinitis (CMV retinitis) in adults who are immunocompromised, including individuals with AIDS. Ganciclovir is also FDA-approved for the prevention of CMV disease in recipients of organ transplants who are at risk for CMV diseases. CMV diseases, including CMV retinitis, can be opportunistic infections (OIs) of HIV. Ganciclovir Sodium is the sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV). Ganciclovir sodium is a prodrug that is phosphorylated and subsequently converted into its triphosphate form, the active metabolite ganciclovir-5-triphosphate (ganciclovir-TP), in the infected cells by cellular kinases. Ganciclovir-TP competes as a substrate with nucleotide triphosphates for viral DNA polymerase. Once it gets incorporated into DNA strand, it prevents further polymerization of DNA, thereby interfering with viral DNA replication. An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. |
| Molecular Formula |
C9H12N5NAO4
|
|---|---|
| Molecular Weight |
277.21
|
| Exact Mass |
277.078
|
| Elemental Analysis |
C, 38.99; H, 4.36
|
| CAS # |
107910-75-8
|
| Related CAS # |
Ganciclovir;82410-32-0;Ganciclovir hydrate;1359968-33-4
|
| PubChem CID |
23700083
|
| Appearance |
White to off-white solid powder
|
| Density |
1.81g/cm3
|
| Boiling Point |
675ºC at 760mmHg
|
| Melting Point |
250ºC (decomposition)
|
| Flash Point |
362ºC
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
19
|
| Complexity |
273
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(CO)OCN1C=NC2=C1NC(=N)N=C2[O-])O.[Na+]
|
| InChi Key |
JJICLMJFIKGAAU-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C9H13N5O4.Na/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);/q;+1/p-1
|
| Chemical Name |
sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 8 mg/mL(28.86 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (90.18 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6074 mL | 18.0369 mL | 36.0737 mL | |
| 5 mM | 0.7215 mL | 3.6074 mL | 7.2147 mL | |
| 10 mM | 0.3607 mL | 1.8037 mL | 3.6074 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
